Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine

American Journal of Medicine

Volumn 106, Issue 2, 1999, Pages 179-184

  Apfelbaum, Marian ^a   Vague, Philippe ^b   Ziegler, Olivier ^c   Hanotin, Corinne ^d   Thomas, Florence ^d   Leutenegger, Eric ^d  

^a BICHAT HOSPITAL   (France)

^b TIMONE HOSPITAL   (France)

^c Ctr Hospitalier Univ de Nancy   (France)

^d Laboratoires Knoll France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIBUTRAMINE;

ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEADACHE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; APPETITE DEPRESSANTS; CYCLOBUTANES; DIET, REDUCING; DOUBLE-BLIND METHOD; ENERGY INTAKE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0033082197     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00411-2     Document Type: Article

References (31)

1. Van Itallie T.B. Worldwide epidemiology of obesity. PharmacoEconomics. 5:1994;1-7.
2. Bray G.A. Complications of obesity. Ann Intern Med. 103:1985;1052-1062.
3. Van Gaal L.F., De Leeuw I.H. Human obesity a medical assessment of health risks. Int J Risk Safety Med. 7:1995;121-134.
4. National task force on the prevention and treatment of obesity. Very low-calorie diets. JAMA. 270:1993;967-974.
5. Apfelbaum M., Bostsarron J., Lacatis D. Effect of caloric restriction and excessive caloric intake on energy expenditure. Am J Clin Nutr. 24:1971;1405-1409.
6. Stunkard A.J. Current views on obesity. Am J Med. 100:1996;230-235.
7. Holden J.H., Darga L.L., Olson S.M., et al. Long-term follow-up of patients attending a combination very-low calorie diet and behaviour therapy weight loss programme. Int J Obes. 16:1992;605-613.
8. Pekkarinen T., Takala I., Mustajoki P. Two year maintenance of weight loss after a VLCD and behaviour therapy for obesity correlation to the scores of questionnaires measuring eating behaviour. Int J Obes. 20:1996;332-337.
9. Blundell J.E., Halford J.C.G. Pharmacological aspects of obesity treatment toward the 21st century. Int J Obes. 19:1995;S51-S55.
10. Andersen T., Astrup A., Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity a randomized clinical trial. Int J Obes. 16:1992;35-40.
11. Szkudlarek J., Elsborg L. Treatment of severe obesity with a highly selective serotonin re-uptake inhibitor as a supplement to a low calorie diet. Int J Obes. 17:1993;681-683.
12. Kogon M.M., Kräuchi K., Van der Velde P., et al. Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women. Am J Clin Nutr. 60:1994;488-493.
13. McLean Baird I., Howard A.N. A double-blind trial of mazindol using a very low calorie formula diet. Int J Obes. 1:1977;271-278.
14. Finer N., Finer S., Naoumova R.P. Prolonged used of a very low caloric diet (Cambridge diet) in massively obese patients attending an obesity clinic safety, efficacy and additional benefit from dexfenfluramine. Int J Obes. 13:1989;91-93.
15. Finer N. Body weight evolution during dexfenfluramine treatment after initial weight control. Int J Obes. 16:1992;S25-S29.
16. Inoue S., Egawa M., Satoh S., et al. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am J Clin Nutr. 55:1992;199S-202S.
17. Heal D.J., Aspley S., Prow M.R., et al. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes. 22:(suppl 1):1998;S18-S28.
18. Stock M.J. Sibutramine a review of the pharmacology of a new anti-obesity agent. Int J Obes. 21:(suppl 1):1997;S25-S29.
19. Lean M.E.J. Sibutramine - a review of clinical efficacy. Int J Obes. 21:(suppl 1):1997;S30-S36.
20. Hanotin C., Thomas F., Jones S.P., et al. A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res. 6:1998;285-291.
21. Guy W. CGI Global Impression ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No.76388, 1976;218-228.
22. Recommandations pour le diagnostic, la prévention et le traitement de l'obésité. AFERO, ALFEDIAM, SNDLF. Diabetes Metab. 1998;24(suppl 2):1-48.
23. Winer B.J. Statistical Principles in Experimental Design. 2nd ed. 1971;261-308 McGraw Hill, New York.
24. Gillings D., Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Informat J. 25:1991;411-424.
25. Jones SP, Smith IG, Kelly F, et al. Long term weight loss with sibutramine. Int J Obes. 1995;19:41. Abstract 071.
26. Goldstein D.J., Potvin J.H. Long-term weight loss the effect of pharmacologic agents. Am J Clin Nutr. 60:1994;647-657.
27. Nestel P.J., Goldrick B. Obesity changes in lipid metabolism and the role of insulin. Clin Endocrinol Metab. 5:1976;313-335.
28. Jeppesen J., Madsbad S. High triglyceride, low HDL-cholesterol and risk of coronary heart disease. Ugeskr Laeger. 158:1996;6896-6901.
29. Brand F.N., McGee D.L., Kannel W.B., et al. Hyperuricaemia as a risk factor of coronary heart disease the Framingham study. Am J Epidemiol. 121:1985;11-18.
30. Freedman D.S., Williamson D.F., Gunter E.W., et al. Relation of serum uric acid to mortality and ischaemic heart disease. The NHANES I epidemiologic follow-up study. Am J Epidemiol. 141:1995;637-644.
31. Wynne R.D., Braybrooke R.M., Brown T., et al. A single-dose, placebo-controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers. Int J Pharm Med. 11:1997;65-70.